Steven Leonard Chapman Sells 2,190 Shares of Natera (NASDAQ:NTRA) Stock

Key Points

• Natera CEO Steven Leonard Chapman sold 2,190 shares at an average price of $260.49, generating $570,473.10. The sale was conducted under a pre-arranged Rule 10b5-1 plan to cover tax obligations from vested equity awards, reducing his position by 2.01%.
• Natera shares recently traded at $253.82, with a market capitalization of approximately $36.35 billion and a 12-month trading range of $131.81 to $288.04.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $267.83; 99.90% of Natera’s shares are held by institutional investors and hedge funds.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 2,190 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $260.49, for a total value of $570,473.10. Following the transaction, the chief executive officer owned 106,553 shares in the company, valued at $27,755,990.97. This represents a 2.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, July 28th, Steven Leonard Chapman sold 3,580 shares of Natera stock. The shares were sold at an average price of $254.07, for a total value of $909,570.60.
• On Thursday, June 4th, Steven Leonard Chapman sold 41,124 shares of Natera stock. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72.
• On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The shares were sold at an average price of $206.16, for a total value of $185,956.32.

Natera Price Performance

NASDAQ NTRA traded up $1.60 on Wednesday, hitting $253.82. The company had a trading volume of 925,147 shares, compared to its average volume of 1,091,572. The company has a market capitalization of $36.35 billion, a PE ratio of -155.72 and a beta of 1.51. The company's fifty day moving average price is $244.16 and its 200-day moving average price is $221.65. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $288.04.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of research reports. Wells Fargo & Company boosted their target price on shares of Natera from $215.00 to $220.00 and gave the stock an "equal weight" rating in a research note on Friday, May 8th. Robert W. Baird set a $265.00 price target on shares of Natera in a research note on Friday, May 8th. Guggenheim boosted their price objective on Natera from $270.00 to $290.00 and gave the stock a "buy" rating in a research note on Monday, June 29th. Morgan Stanley increased their target price on Natera from $250.00 to $310.00 and gave the company an "overweight" rating in a report on Thursday, July 9th. Finally, UBS Group set a $260.00 target price on Natera in a research report on Wednesday, June 24th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $267.83.

Hedge Funds Weigh In On Natera

A number of institutional investors and hedge funds have recently bought and sold shares of NTRA. Elevation Wealth Partners LLC purchased a new stake in shares of Natera in the 2nd quarter valued at approximately $30,000. Reflection Asset Management acquired a new position in Natera in the fourth quarter valued at approximately $29,000. Palladiem LLC acquired a new position in Natera in the fourth quarter valued at approximately $31,000. Bank of Jackson Hole Trust grew its position in Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock worth $37,000 after acquiring an additional 83 shares during the period. Finally, International Assets Investment Management LLC grew its position in Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company's stock worth $35,000 after acquiring an additional 97 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.